Follow
James R Whittle
James R Whittle
Peter MacCallum Cancer Centre
Verified email at petermac.org
Title
Cited by
Cited by
Year
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation
Z Yu, C Wang, M Wang, Z Li, MC Casimiro, M Liu, K Wu, J Whittle, X Ju, ...
The Journal of cell biology 182 (3), 509-517, 2008
4452008
Patient-derived xenograft models of breast cancer and their predictive power
JR Whittle, MT Lewis, GJ Lindeman, JE Visvader
Breast cancer research 17, 1-13, 2015
3152015
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer
D Merino, JR Whittle, F Vaillant, S Antonin, JN Gong, G Giner, ...
Science Translational Medicine 9 (401), 2017
1712017
Modeling breast cancer using CRISPR-Cas9–mediated engineering of human breast organoids
JF Dekkers, JR Whittle, F Vaillant, HR Chen, C Dawson, K Liu, MH Geurts, ...
JNCI: Journal of the National Cancer Institute 112 (5), 540-544, 2020
1262020
A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2–positive metastatic breast cancer
SW Lok, JR Whittle, F Vaillant, CE Teh, LL Lo, AN Policheni, ART Bergin, ...
Cancer discovery 9 (3), 354-369, 2019
1252019
First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma
JR Whittle, JD Lickliter, HK Gan, AM Scott, J Simes, BJ Solomon, ...
Journal of Clinical Neuroscience 22 (12), 1889-1894, 2015
1082015
Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor–positive breast cancer
JR Whittle, F Vaillant, E Surgenor, AN Policheni, G Giner, BD Capaldo, ...
Clinical Cancer Research 26 (15), 4120-4134, 2020
752020
Sirtuins, nuclear hormone receptor acetylation and transcriptional regulation
JR Whittle, MJ Powell, VM Popov, LA Shirley, C Wang, RG Pestell
Trends in Endocrinology & Metabolism 18 (9), 356-364, 2007
652007
Targeting triple-negative breast cancers with the Smac-mimetic birinapant
N Lalaoui, D Merino, G Giner, F Vaillant, D Chau, L Liu, T Kratina, B Pal, ...
Cell Death & Differentiation 27 (10), 2768-2780, 2020
342020
An ecosystem‐scale model for the spread of a host‐specific forest pathogen in the Greater Yellowstone Ecosystem
JA Hatala, MC Dietze, RL Crabtree, K Kendall, D Six, PR Moorcroft
Ecological Applications 21 (4), 1138-1153, 2011
282011
A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers
A Roohullah, A Cooper, AJ Lomax, J Aung, A Barge, L Chow, M McHale, ...
Investigational new drugs 36, 886-894, 2018
262018
Histone deacetylase inhibitors in cancer: What have we learned?
JR Whittle, J Desai
Cancer 121 (8), 1164-1167, 2015
162015
Carboplatin dosing in the era of IDMS-creatinine; the Cockroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use …
L McLean, JR Whittle, J Graham, H Ismail, M Lichtenstein, RJ Hicks, ...
Gynecologic Oncology 157 (3), 793-798, 2020
132020
PALVEN: Phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor-and BCL2-positive advanced breast cancer
C Muttiah, JR Whittle, C Oakman, GJ Lindeman
Future Oncology 18 (15), 1805-1816, 2022
112022
First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER+ breast cancer with KAT6A dysregulation
S Sharma, J Chung, S Uryu, A Rickard, N Nady, S Khan
Cancer Res. 81 (Suppl. 13), 1130-1130, 2021
112021
Safety and efficacy of the BCL2 inhibitor venetoclax in estrogen receptor (ER) and BCL2-positive metastatic breast cancer: The mBEP study.
GJ Lindeman, SW Lok, AR Bergin, JR Whittle, K Shackleton, P Sherman, ...
Journal of Clinical Oncology 35 (15_suppl), 1044-1044, 2017
112017
How has the COVID-19 pandemic impacted clinical care and research in Neuro-Oncology?
A Airth, JR Whittle, J Dimou
Journal of clinical neuroscience 105, 91-102, 2022
72022
In vivo genome‐editing screen identifies tumor suppressor genes that cooperate with Trp53 loss during mammary tumorigenesis
L Heitink, JR Whittle, F Vaillant, BD Capaldo, JF Dekkers, CA Dawson, ...
Molecular Oncology 16 (5), 1119-1131, 2022
72022
First-in-man trial of 4-(N-(S-penicillaminylacetyl) amino) phenylarsonous acid (PENAO) as a continuous intravenous infusion (CIVI), in patients (pt) with advanced solid tumours.
JD Ben Tran, Anne L Hamilton, Lisa Horvath, Michael Lam, Peter Stephen Savas ...
Journal of Clinical Oncology 34 (15_suppl), e14025-e14025, 2016
72016
Use of vemurafenib in a patient unable to swallow whole
B Janson, J Whittle, K Witney, K Moodie, J Callahan, S Sandhu
Journal of Oncology Pharmacy Practice 22 (5), 733-737, 2016
62016
The system can't perform the operation now. Try again later.
Articles 1–20